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Prostate cancer is the second most common cancer in 
men.1–3 Nearly 90% of prostate cancers are clinically 
localised at the time of diagnosis.4,5 The clinical course of 
localised prostate cancer is highly variable. While many 
patients have indolent cancers (cured with initial therapy, 
or observed and treated on progression), other patients 
have aggressive cancer that will recur after initial treat-
ment. It is estimated that around 15% of all prostate cancer 
diagnoses could be classified as ‘high-risk’ disease.6 The 
10-year survival rate for men with high-risk prostate can-
cer has been reported to range from 65% to 91%, and an 
increasing aggregate of high-risk features correlates with 
worse outcome.7 For a full review of the classification and 
therapy of high-risk prostate cancer, readers are directed to 
a review by Chang and colleagues.8
Systemic chemotherapy in addition to definitive man-
agement to reduce the chance of recurrence and ultimately 
death from cancer has a proven role in certain tumour 
types such as breast, colorectal, bladder or lung cancers. 
Chemotherapy is given before (neoadjuvant) or just after 
(adjuvant) definitive therapy (surgery and/or radiother-
apy). Often the overall benefit to the treated population 
may appear numerically small, for example; five-year 
overall survival (OS) rates for patients with bladder cancer 
increases by around 5% following neoadjuvant chemo-
therapy.9 Comparatively few advances have been made to 
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define additional systemic therapy for men with prostate 
cancer.
Localised prostate cancer is commonly risk stratified 
into low-, intermediate- or high-risk, most widely by the 
D’Amico classification using prostate-specific antigen 
(PSA) and histological criteria.10 It is plausible that such 
classifications may not adequately define populations of 
men with prostate cancer for additional medical therapy, 
which has hampered clinical trial design. It is possible that 
clinical signals of activity from subgroups of patients 
might have been diluted in a heterogeneous, larger popula-
tion of men with prostate cancer that did not require addi-
tional treatment. Advances in risk stratification may better 
define populations of men to enter into peri-operative stud-
ies; for example, the utility of genomic tests such as 
Prolaris and Oncotype DX are being investigated to sup-
port treatment decisions for men with prostate cancer.
Androgen ablation has been the mainstay of medical 
treatment for men with prostate cancer since the 1940s. 
However, drug therapy for men with late-stage ‘castration-
resistant’ prostate cancer (CRPC) has altered markedly in 
the last decade. Several drugs (i.e. cabazitaxel, abirater-
one, enzalutamide, alpharadin, sipuleucil T), with varying 
mechanisms of action, have been approved based on 
improved OS within randomised clinical trials. Also, 
reflecting a new paradigm of early systemic treatment, 
recent and compelling evidence has altered clinical prac-
tice. Multiple studies have confirmed docetaxel chemo-
therapy given to men with hormone-sensitive prostate 
cancer improved overall survival.11–14
Current neoadjuvant and adjuvant 
hormonal therapy practice
The role of neoadjuvant hormonal therapy prior to prosta-
tectomy has not been well established15,16 and the clinical 
trial data have been reviewed by McKay and colleagues.17 
Furthermore, the morphological changes induced by neo-
adjuvant androgen ablation may complicate assessment of 
surgical margins and capsular involvement.18
Adjuvant androgen-deprivation therapy (ADT), after 
radical prostatectomy (RP), is restricted to cases with 
positive pelvic lymph nodes. Trials in this setting report 
mixed findings; for example a study by Messing et al.19 
demonstrated improvement in OS for patients treated with 
immediate ADT (hazard ratio (HR) 1.84; 95% confidence 
interval (CI) 1.01–3.35). However, a subsequent meta-
analysis of 731 men with positive nodes failed to demon-
strate a survival benefit of ADT initiated within four 
months of RP compared to observation.20
For patients that are treated with radiotherapy, neoadju-
vant or adjuvant ADT combined with radiation therapy (RT) 
are part of current standard practice for men with intermedi-
ate and high-risk localised prostate cancer.21 Improved OS 
and cancer-specific survival data from multiple studies22–26 
have reinforced the recommendation that men without sig-
nificant comorbidities should be offered six months of ADT 
before, during or after radical external beam radiotherapy. 
Consideration of continuing ADT for up to three years 
should be made in men with high-risk disease alone, sup-
ported by data suggesting improvements in OS of up to 13% 
compared to short-term suppression.27–29
Adjuvant and neoadjuvant 
chemotherapy
The role of neoadjuvant chemotherapy has not been estab-
lished in the treatment of prostate cancer when given with 
or without androgen deprivation.17 Previous, small, phase 
2 studies have investigated single-agent docetaxel or com-
bination therapy, e.g. docetaxel and estramustine or estra-
mustine and etoposide.30–33 In general, authors conclude 
neoadjuvant chemotherapy may have a role in treatment of 
high-risk or locally advanced prostate cancer. However, 
evidence of survival benefit from randomised clinical tri-
als has yet to be reported. Maturation of data within the 
Phase III GETUG 12 and SWOG (NCT00430183) trials is 
awaited. Early results reported from GETUG 12 support 
an improvement in relapse-free survival following doc-
etaxel chemotherapy.34,35
Adjuvant chemotherapy to treat men with prostate can-
cer also remains contentious. For example, the RTOG 
9902 trial compared ADT and RT vs. ADT and RT fol-
lowed by chemotherapy (paclitaxel, estramustine and 
etoposide) for men with localised, high-risk prostate can-
cer. This study reported increased toxicity with no OS ben-
efit from the investigational arm.36,37 The RTOG 0521 
study compared outcomes in 562 men with high-risk, 
localised prostate cancer treated with two years of andro-
gen suppression plus RT, with or without the addition of 
adjuvant chemotherapy (docetaxel and prednisone). 
Preliminary results reported a trend to improved OS at four 
years (93% vs. 86%) for men treated with adjuvant doc-
etaxel; a short OS assessment was incorporated and addi-
tional follow-up to determine long-term benefits was 
recommended.38 A further study, SWOG 9921, that com-
pared adjuvant therapy (ADT alone or combined with 
mitoxantrone) was terminated early due to a safety issue.
Adjuvant and neoadjuvant targeted 
therapies
To date, early prostate cancer treatment decisions are still 
based almost exclusively on histological architecture 
(Gleason score)39,40 PSA levels41 and local disease extent.42 
We are yet to realise the potential of personalisation of 
therapy with targeted treatments in prostate cancer.
Prior to addressing the full scope of potential in (neo)
adjuvant targeted therapies, addressing new ways of target-
ing the androgen receptor should be discussed first. Markers 
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of biological response and resistance have been reported in 
small studies of neoadjuvant ADT. In a study by Mostaghel 
et al.43 evaluating the effect of neoadjuvant ADT on gene 
expression in RP samples from men with localised prostate 
cancer, chemical castration was found to reduce tissue 
androgens by 75% and reduce the expression of several 
androgen-regulated genes (e.g. NDRG1, FKBP5 and 
TMPRESS2). However, androgen receptor (AR) and PSA 
gene expression were not suppressed, suggesting that sub-
optimal suppression of the AR axis at the tumoural level 
may lead to resistance in a low androgen environment. A 
different study by Mostaghel et al.44 looked at the correla-
tion between tissue androgen levels (dihydrotestosterone 
and testosterone) and change in tumour volumes after three 
months of various combinations of neoadjuvant hormonal 
therapies, but found none. These studies serve to emphasise 
the need for novel therapies targeting complete suppression 
of the AR axis, to aid in improving local and systemic con-
trol of intermediate to high-risk prostate cancer.
Gonadotropin-releasing hormone (GnRH) antagonists 
such as degarelix45 offer an alternative to luteinising hor-
mone-releasing hormone (LHRH) agonists, as a result of 
immediate competitive binding to GnRH receptors. 
Abiraterone is also being assessed in the neoadjuvant set-
ting in combination with an LHRH agonist, and prelimi-
nary results have shown that tissue androgens were 
significantly more suppressed with abiraterone and patho-
logic responses were favourable.46 In another study, andro-
gen signalling and proliferation suppression was again 
more profound with the combination of abiraterone plus an 
LHRH agonist, compared to LHRH monotherapy.47 
Similarly, investigations into enzalutamide are ongoing.
Better understanding of prostate cancer biology and the 
ability to adapt therapy to specific patients and their can-
cers remains the subject of active research, reviewed by 
Fraser and colleagues.48 Recent studies show that prostate 
cancer can be stratified according to molecular signa-
tures.49–53 The genetic changes associated with aggressive 
prostate cancer, when present in early tumours, herald the 
onset of early biochemical relapse.54 The Cancer Genome 
Atlas (TCGA),55 a comprehensive molecular analysis of 
333 primary prostate carcinomas, has revealed a ‘molecu-
lar taxonomy’ in which 74% of analysed tumours fell into 
one of seven subtypes defined by specific gene fusions 
(ETS family, SPOP, FOXA1 or IDH1) or molecular defects 
in signalling pathways such as PI3K, mitogen-activated 
protein kinase (MAPK) or DNA repair. This effort though 
still leaves 26% of tumours unclassified. Similarly, the 
CamCap study group also undertook a comprehensive, 
integrated analysis of genomic and transcriptomic data 
from a study of 482 tumour, benign and germline samples, 
including 259 men with primary prostate cancer.56 Five 
distinct molecular profiles for primary prostate cancer 
were identified that were predictive of biochemical relapse, 
based on the integrative analysis of transcript levels and 
somatic copy number alterations (CNAs). Other studies 
have also used whole-genome sequencing to characterise 
tumour heterogeneity and improve our understanding of 
how the subclonal architecture and diversity of tumours 
changes during metastasis and progression to lethality.57–59 
Building from these studies, work is ongoing to develop 
personalised or precision medicine treatment for men with 
prostate cancer.
Published studies to date have focussed on targets that 
may be more relevant in CRPC and usually have been per-
formed in populations without the aid of biomarker selec-
tion to enrich the patient population for those most likely 
to benefit. Examples include studies targeting angiogene-
sis and vascular endothelial growth factor receptor 
(VEGFR) (with agents such as bevacizumab, sunitinib and 
thalidomide), EGFR (gefitinib and cetuximab), platelet-
derived growth factor receptor (PDGFR) (imatinib), clus-
terin (OGX-011 or custirsen) and immunotherapeutics 
(Sipuleucel-T and Ipilimumab).60–72 With all agents, results 
have been variable, but most promising with targeting of 
clusterin and immunomodulation; however, they raise 
important and unresolved issues in regards to appropriate 
lengths of treatment, and need for predictive biomarkers of 
response in the setting of prohibitive costs.
A paucity of representative pre-clinical models related 
to early human prostate cancer makes it attractive to study 
a drug’s effects in the ‘window’ prior to radical therapy. 
Ongoing clinical studies from several groups, including 
ours, may provide further insights (see Table 1). 
NCT00430183 is a large (>700 patients) study which has 
completed recruitment and will compare the outcome for 
patients who have been treated with neoadjuvant doc-
etaxel. The other studies listed are mostly smaller, Phase 1 
and 2 studies looking for signals of activity. For example, 
in addition to the data from the prostate TCGA described 
above, aberrant PI3k pathway signalling has been detected 
in 42% of primary and 100% of metastatic prostate can-
cers.73,74 Loss of PTEN and activation of the PI3k/mTOR 
pathway are observed in aggressive primary disease.75,76 
The effects in prostate cancer tissue of rapamycin (an 
mTOR1 inhibitor) have been studied. The drug was safe 
and inhibited mTORC1 signalling; however, no effects on 
tumour proliferation were detected.77 The CaNCaP02 
study (Table 1) is investigating the pharamcodynamic 
effects of AZD2014 (a dual mTORC1 and 2 inhibitor) for 
men with intermediate- or high-risk prostate cancer. 
Inhibition of both mTOR complexes may potentially offer 
improved therapeutic advantages, and results are awaited.
Additional, more immediately actionable opportunities 
for targeted therapy might exist. An estimated 19% of pri-
mary prostate cancers have defects in ‘DNA repair path-
ways’. Exciting data from the ‘TOPARP’ study78 confirmed 
olaparib (PARP inhibitor) treatment was clinically effec-
tive when given to men with metastatic CRPC, selected on 
the basis of defects in DNA repair genes (including 
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BRCA1/2, ATM, Fanconi’s anaemia genes, and CHEK2). A 
further window study, using olaparib (CaNCaPO3), has 
been developed and is scheduled to open to recruitment 
later in 2016.
It is worth noting the variety of endpoints that are 
employed within the studies listed in Tables 1 and 2. One of 
the challenges for investigators in this field remains defining 
and obtaining consensus on what are adequate surrogate 
endpoints for prostate cancer relapse, or alternatively, clini-
cally relevant endpoints such as OS will have to be used 
(even if the studies take longer to complete). Surrogate end-
points such as pathological complete response (pCR) rate, 
validated in other solid tumours to correlate with improved 
survival, have not been proven in prostate cancer.17 Advances 
Table 1. Recruiting neoadjuvant studies (from www.clinicaltrials.gov, accessed December 2015).
ClinicalTrials.gov identifier Intervention Primary outcome
NCT00430183 Six cycles docetaxel + LHRH agonist + surgical intervention vs. 




NCT01804712 28 days rituximab (anti CD20 antibody) Histological ‘response rate’
NCT02494713 Four months degarelix combined with chemotherapy 
(doxorubicin, ketoconazole, docetaxel and estramustine)
Pathological response (% 
tumour burden remaining)
NCT02381236 84 days G-202 (pro-drug, coupled to PSMA) Prostate volume and perfusion 
of using multiparametric 
prostate (mp) MRI
NCT02268175 Six cycles of Enzalutamide + Leuprolide + Abiraterone Acetate 
+ Prednisone vs. Enzalutamide + Leuprolide
Pathological: pCR and MRD
NCT01409200 Eight months ADT ± open-label Axitinib (VEGFR, c-kit, PDGFR 
inhibitor)
PFS at 12 months after surgery
NCT02160353 126 days abiraterone acetate + prednisolone + GnRH agonist Clinical tumour, biochemical 
and prostate volume response
NCT02643667 28 days Ibrutinib (BTK inhibitor) Prostate immune infiltration 
compared to a reference 
cohort
NCT01990196 Six to eight weeks with three groups: Degarelix + enzalutamide 
vs. trametinib (MEKi) + degarelix + enzalutamide vs. dasatinib 
(SRC and Bcr-Abl inhibitor) + degarelix + enzalutamide
N cadherin and vimentin 
expression
NCT02153918 Three months rV-PSA (L155)-TRICOM (PROSTVAC-V) as a 
priming vaccination followed by monthly boosting with rF-PSA 
(L155)-TRICOM (PROSTVAC-F)
CD4 and CD8 cell infiltrates
NCT02064608 Two weeks AZD2014 (mTOR 1/2 inhibitor) mTORC1 and mTORC2 
pathway inhibition using IHC 
for p4EBP1, pS6 and pAKT
NCT01832259 28 days of pazopanib (cKIT, FGFR, PDGFR and VEGFR inhibitor) 
vs. placebo
Decrease in pre-metastatic 
niche formation in benign 
lymph nodes
NCT02390063 ChAdOx1.5T4 prime followed by two boosts of MVA.5T4 
vaccine (q4 week) vs. one week of low-dose cyclophosphamide 
pre-conditioning before each vaccination vs. three MVA.5T4 
vaccinations alone (q4 week) vs. one week of low-dose 
cyclophosphamide pre-conditioning before each of the three 
MVA.5T4 vaccinations
Vaccine safety and 
immunogenicity (by change 
in anti-5T4 cellular and 
humoral responses following 
vaccination)
NCT: National Clinical Trial; LHRH: luteinizing hormone-releasing hormone; EBRT: external-beam radiation therapy; PSMA: prostate-specific 
membrane antigen; ADT: androgen-deprivation therapy; VEGFR: vascular endothelial growth factor receptor; PDGFR: platelet-derived growth factor 
receptor; GnRH: gonadotropin-releasing hormone; BTK: Bruton tyrosine kinase; rV-PSA: recombinant vaccinia virus expressing prostate-specific 
antigen; rF-PSA: recombinant fowlpox prostate-specific antigen; mTOR: mammalian target of rapamycin; FGFR: fibroblast growth factor receptor; 
pCR: pathological complete response; MRD: minimal residual disease; PFS: progression-free survival; IHC: immunohistochemistry.
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in technology may improve this situation; for example, it is 
possible to measure circulating tumour DNA (ctDNA) in a 
variety of clinical settings including prostate cancer. With 
further refinement it will be interesting to see if measuring 
ctDNA, or perhaps another circulating marker, might more 
adequately monitor the response to drug treatment.
Conclusion
As the incidence of primary prostate cancer rises in the 
United Kingdom,79 the detection of men with high-risk 
non-metastatic prostate cancer and their subsequent man-
agement is becoming increasingly important. Over the last 
decade, there has been a significant shift in the manage-
ment of prostate cancer, including studies that confirm the 
benefits of radical treatment in a number of publications.80 
Building on results for men with CRPC, docetaxel has 
recently been proven active for men with hormone-sensi-
tive prostate cancer and the results of studies with more 
recently approved drugs for prostate cancer in the (neo)
adjuvant setting are awaited. Furthermore, advances in the 
biological understanding of prostate cancer and novel drug 
development will hopefully broaden the armamentarium 
beyond agents proven or predicted to be effective in CRPC.
While it is clear that early, radical treatment of primary 
prostate cancer is very effective, it remains difficult to 
identify those patients who are likely to relapse and to treat 
them appropriately.56 Further risk stratification, for exam-
ple, utilising molecular features, could potentially help 
distinguish indolent from aggressive prostate cancer, ulti-
mately providing biological markers that could guide a 
more personalised approach to therapy selection.
Key points
1. An increasing proportion of men diagnosed with 
prostate cancer in the United Kingdom are present-
ing with non-metastatic disease.
2. Early treatment of primary prostate cancer is very 
effective, and radical treatment has been clearly 
shown to be beneficial in this group of patients in a 
number of publications.
3. As yet, there continues to be no molecularly targeted 
or chemotherapeutic options with proven, statisti-
cally significant survival benefit in this setting.
4. Identification of men with prostate cancer that is 
likely to relapse and to treat them appropriately 
remains an unmet clinical challenge. However, 
there are indications that further risk stratification 
using molecular features could potentially help dis-
tinguish indolent from aggressive prostate cancer.
5. Using molecular features to personalise treatment 
could allow us to optimise precision treatment of 
primary prostate cancer.
Table 2. Recruiting adjuvant studies (from www.clinicaltrials.gov, accessed December 2015).
ClinicalTrials.gov identifier Intervention Primary outcome




NCT02176161 Nine months of metformin (patients at high risk of recurrence) PSA doubling time over 
nine months
NCT02064673 Six months curcumin vs. placebo post-prostatectomy Recurrence-free survival 
(total serum PSA <0.2 
ng/ml at three years)
NCT01436968 Up to six months: ProstAtak™ (immunotherapy) consisting of AdV-
tk injection + oral valacyclovir (2× pre-radiation, 1× post-standard 
EBRT), vs. placebo + valaciclovir. Short-term ADT is optional post-up-
front RT
Disease-free survival
NCT01341652 Two years of pTVG-HP (DNA vaccine) with rhGM-CSF vs. rhGM-
CSF alone
Metastasis-free survival
NCT02446444 24 months of LHRH agonist + enzalutamide vs. LHRH + non-steroidal 
anti-androgen (and EBRT ± brachytherapy boost approx. 16 weeks 
after randomisation) for high-risk, clinically localised, prostate cancer: 
‘ENZARAD’
Overall survival
NCT02229734 Stereotactic radiation + 18 months ADT, high-risk prostate cancer: 
‘FASTR-2’
GI and GU toxicity at 
one year
NCT: National Clinical Trial; PSA: prostate-specific antigen; EBRT: external-beam radiation therapy; ADT: androgen-deprivation therapy; RT: radia-
tion therapy; rhGM-CSF: recombinant human granulocyte-macrophage-colony-stimulating factor; LHRH: luteinizing hormone-releasing hormone; GI: 
gastrointestinal; GU: genitourinary.
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